Clinical use of dalbavancin in the Italian SUSANA cohort (SUrveillance of SAfety and outcome of New Antibiotics).
Sara Tordi(University of Perugia), Giuseppe Vittorio De Socio(University of Perugia), Goffredo Angioni(Santissima Trinità), Elena Ricci(Mario Negri Institute for Pharmacological Research), Luca Bisi(University of Milano-Bicocca), Stefania Cicalini(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Letizia Attala(Ospedale Santa Maria Annunziata), Giordano Madeddu(University of Sassari), Paolo Bonfanti(University of California San Diego), Stefania Piconi(Alessandro Manzoni Hospital), Alessandro Pandolfo(Alessandro Manzoni Hospital), Luca Mezzadri(University of Milano-Bicocca), Giovanni Cenderello(Ospedale di Sanremo), Francesco Luzzaro(University of Insubria), Daniela Francisci(University of Perugia), Paolo Maggi(Università degli Studi di Enna Kore)
PubMed
May 1, 2025
Cited by 1
Related Papers
CTX-M: changing the face of ESBLs in Europe
|Journal of Antimicrobial Chemotherapy|2006|923
Hospital-Acquired Infections in Critically Ill Patients With COVID-19
|CHEST Journal|2021|404
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|394
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study
|Clinical Infectious Diseases|2021|264
Mucosal and Plasma IgA from HIV-1-Exposed Uninfected Individuals Inhibit HIV-1 Transcytosis Across Human Epithelial Cells
|The Journal of Immunology|2000|244